GlassScriptPhysician profile
Randy D Sorum
NPI 1720059181
$2,721.27
in general payments reported to CMS, 2019-2025
46 companies · $492 in 2025
The $492 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $216 · 2021: $48.71 · 2022: $207 · 2023: $482 · 2024: $154 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $381.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.51 | 2019-2025 | Imfinzi |
| Boston Scientific Corporation | $219.31 | 2019-2024 | Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $165.36 | 2019-2025 | Erleada, Balversa, Akeega |
| Merck Sharp & Dohme LLC | $151.49 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Incyte Corporation | $139.33 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Eisai INC. | $103.97 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $89.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $88.04 | 2022-2025 | |
| Daiichi Sankyo INC. | $83.81 | 2022-2025 | Enhertu |
| Amgen INC. | $79.70 | 2022-2023 | Kyprolis, Blincyto, Lumakras |
| Novocure INC. | $72.75 | 2019-2024 | Optune |
| Fortovia Therapeutics, INC. | $67.02 | 2019 | |
| Seagen INC. | $62.09 | 2019-2023 | Tukysa, Tivdak |
| Abbvie INC. | $55.98 | 2019-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Sorum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.